HSP Complete 15

• Our Complete 15 human strain probiotics provide 7 clinically studied human strains with a potency of 15 billion colony-forming units (CFU) per vegetarian capsule. With a balance of probiotics to target both small and large intestinal flora, we've got you covered. Unlike enteric-coated or delayed-release products, our capsules are designed to target the duodenum and provide maximum gut-brain support when taken with food.

HSP Complete 15 is formulated with 2 billion CFU of Lactobacillus acidophilus DDS-1; a strain clinically shown to reduce gastrointestinal discomfort during travel and lactose intolerance. In addition, this strain has been shown to regulate bowel habits and stool consistency. In a double-blind, placebo-controlled RCT, Bifidobacterium animalis subsp. Lactis HN019 was shown to significantly increase stool frequency in patients who struggled to have fewer than 3 bowel movements per week.

Benefits for the immune system

In another trial in adults aged 70 and older, HN019 was shown to increase the activity of helper T cells and natural killer cells in patients with a weak immune response.

In a clinical trial comparing the efficacy of various probiotic strains on immune responses, groups administered Lactobacillus acidophilus La-14 or Bifidobacterium animalis subsp. Lactis BL-04 was shown to significantly increase serum IgG compared to controls. In a randomized, double-blind, placebo-controlled trial, Bifidobacterium animalis subsp. Lactis BL-04 was shown to reduce the incidence of respiratory tract infections and viral shedding after being administered during rhinovirus infection and supplemented with the probiotic strain for an additional 28 days.

In another double-blind, placebo-controlled trial in 465 healthy adults, Bifidobacterium animalis subsp. Lactis BL-04 (at a dose of 2 billion CFU) was more effective than placebo and a multi-strain probiotic (19% reduction vs. 27%) in reducing the incidence of respiratory tract infections and improving immunity.

Metabolic benefits

Chronic diseases such as obesity and hypertension are modifiable cardiometabolic risk factors that are highly predictive of hospitalization. Our HSP probiotics were formulated to address inflammatory biomarkers, high cholesterol, and elevated BMI typically seen in individuals with reduced immune function. In a randomized, double-blind, placebo-controlled trial of 32 overweight and obese women, our HSP strains were found to be significantly correlated with BMI, weight, fat mass, lean mass, taper index, protein intake, monounsaturated fat intake, glycated hemoglobin, TNF-α, and IL6/IL10. HSP bifidobacteria strains also demonstrated specific cholesterol-absorbing properties, resulting in lower serum total cholesterol and LDL-C.